181 related articles for article (PubMed ID: 33426708)
41. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
42. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
43. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
44. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
[TBL] [Abstract][Full Text] [Related]
45. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
46. Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Elson JL; Yates A; Pienaar IS
Brain Struct Funct; 2016 May; 221(4):2319-41. PubMed ID: 25989851
[TBL] [Abstract][Full Text] [Related]
47. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
[TBL] [Abstract][Full Text] [Related]
48. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
49. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Simms SL; Huettner DP; Kortagere S
Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
[TBL] [Abstract][Full Text] [Related]
50. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Zhang K; Chammas C; Soghomonian JJ
Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
[TBL] [Abstract][Full Text] [Related]
51. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Perez XA; Zhang D; Bordia T; Quik M
Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
[TBL] [Abstract][Full Text] [Related]
52. Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease.
Pienaar IS; Gartside SE; Sharma P; De Paola V; Gretenkord S; Withers D; Elson JL; Dexter DT
Mol Neurodegener; 2015 Sep; 10():47. PubMed ID: 26394842
[TBL] [Abstract][Full Text] [Related]
53. Ondansetron, a highly selective 5-HT
Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
[TBL] [Abstract][Full Text] [Related]
54. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
55. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Lindenbach D; Conti MM; Ostock CY; Dupre KB; Bishop C
Neuroscience; 2015 Dec; 310():12-26. PubMed ID: 26363150
[TBL] [Abstract][Full Text] [Related]
56. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
57. The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
Li M; Zhou M; Wen P; Wang Q; Yang Y; Xiao H; Xie Z; Li X; Wang N; Wang J; Luo F; Chang J; Zhang W
Exp Neurol; 2016 Aug; 282():27-36. PubMed ID: 27163550
[TBL] [Abstract][Full Text] [Related]
58. Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Belaid H; Adrien J; Laffrat E; Tandé D; Karachi C; Grabli D; Arnulf I; Clark SD; Drouot X; Hirsch EC; François C
J Neurosci; 2014 Jul; 34(27):9124-33. PubMed ID: 24990932
[TBL] [Abstract][Full Text] [Related]
59. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
60. Modeling Parkinson's disease falls associated with brainstem cholinergic systems decline.
Kucinski A; Sarter M
Behav Neurosci; 2015 Apr; 129(2):96-104. PubMed ID: 25798629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
